Performance of serum biomarkers for the early detection of invasive aspergillosis in febrile, neutropenic patients: A multi-state model

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Schwarzinger, Michaël ^a,b,c,d   Sagaon Teyssier, Luis ^e,f,g   Cabaret, Odile ^h,i   Bretagne, Stéphane ^h,i,j   Cordonnier, Catherine ^h,i  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Translational Health Economics Network   (France)

^d STANFORD UNIVERSITY   (United States)

^e AIX MARSEILLE UNIV   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^j INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; BETA DEXTRO GLUCAN; BETA GLUCAN; FUNGUS ANTIGEN; GALACTOMANNAN; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; FUNGAL DNA; FUNGAL POLYSACCHARIDE; MANNAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; COHORT ANALYSIS; CONCEPTUAL FRAMEWORK; CONTROLLED STUDY; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE MARKER; EARLY DIAGNOSIS; ELISA KIT; FEMALE; FEVER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INFECTION RISK; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MIDDLE AGED; MITOCHONDRION; NEUTROPENIA; NONHUMAN; OPEN STUDY; POLYMERASE CHAIN REACTION; PREDICTION; PROSPECTIVE STUDY; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; AGED; BIOLOGICAL MODEL; BLOOD; FEBRILE NEUTROPENIA; FUNGAL GENE; GENETICS; IMMUNOLOGY; LUNG ASPERGILLOSIS; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; INVASIVE PULMONARY ASPERGILLOSIS; LEUKEMIA, MYELOID, ACUTE;

ADULT; AGED; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; ANTINEOPLASTIC AGENTS; BETA-GLUCANS; BIOLOGICAL MARKERS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DNA, FUNGAL; EARLY DIAGNOSIS; FEMALE; FUNGAL POLYSACCHARIDES; GENES, FUNGAL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; LEUKEMIA, MYELOID, ACUTE; MALE; MANNANS; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84886634582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065776     Document Type: Article

References (40)

1. Segal BH (2009) Aspergillosis. N Engl J Med 360: 1870-1884.
2. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, et al. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34: 7-14. (Pubitemid 33152659)
3. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46: 1813-1821.
4. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, et al. (1984) Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 100: 345-351. (Pubitemid 14156535)
5. Muhlemann K, Wenger C, Zenhausern R, Tauber MG (2005) Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 19: 545-550. (Pubitemid 40521158)
6. Gotzsche PC, Johansen HK (1997) Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 314: 1238-1244. (Pubitemid 27173908)
7. Marr KA, Leisenring W (2005) Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 41 Suppl 6: S381-386. (Pubitemid 41266737)
8. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97: 1604-1610. (Pubitemid 32217224)
9. Kami M, Fukui T, Ogawa S, Kazuyama Y, Machida U, et al. (2001) Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 33: 1504-1512. (Pubitemid 34246144)
10. Kawazu M, Kanda Y, Nannya Y, Aoki K, Kurokawa M, et al. (2004) Prospective comparison of the diagnostic potential of real-time PCR, doublesandwich enzyme-linked immunosorbent assay for galactomannan, and a (1->3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 42: 2733-2741. (Pubitemid 38747529)
11. Barnes RA, White PL, Bygrave C, Evans N, Healy B, et al. (2009) Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol 62: 64-69.
12. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, et al. (2012) ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 47: 846-854.
13. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, et al. (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41: 1242-1250. (Pubitemid 41534660)
14. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, et al. (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44: 402-409. (Pubitemid 46147624)
15. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, et al. (2008) Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 46: 1412-1422. (Pubitemid 351589942)
16. Nouer SA, Nucci M, Kumar NS, Grazziutti M, Barlogie B, et al. (2011) Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 53: 671-676.
17. Koo S, Bryar JM, Page JH, Baden LR, Marty FM (2009) Diagnostic performance of the (1->3)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 49: 1650-1659.
18. Desmet S, Van Wijngaerden E, Maertens J, Verhaegen J, Verbeken E, et al. (2009) Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 47: 3871-3874.
19. Pfeiffer CD, Fine JP, Safdar N (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 42: 1417-1427.
20. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, et al. (2008) Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev: CD007394.
21. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP (2009) Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9: 89-96.
22. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, et al. (2011) beta-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis 52: 750-770.
23. Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, et al. (2012) beta-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis 54: 633-643.
24. Marr KA, Laverdiere M, Gugel A, Leisenring W (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40: 1762-1769. (Pubitemid 40799945)
25. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, et al. (2009) Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 48: 1042-1051.
26. Botterel F, Farrugia C, Ichai P, Costa JM, Saliba F, et al. (2008) Real-time PCR on the first galactomannan-positive serum sample for diagnosing invasive aspergillosis in liver transplant recipients. Transpl Infect Dis 10: 333-338.
27. Costa C, Costa JM, Desterke C, Botterel F, Cordonnier C, et al. (2002) Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 40: 2224-2227. (Pubitemid 34596412)
28. Costa JM, Ernault P, Gautier E, Bretagne S (2001) Prenatal diagnosis of congenital toxoplasmosis by duplex real-time PCR using fluorescence resonance energy transfer hybridization probes. Prenat Diagn 21: 85-88.
29. White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, et al. (2010) Aspergillus PCR: one step closer to standardization. J Clin Microbiol 48: 1231-1240.
30. White PL, Mengoli C, Bretagne S, Cuenca-Estrella M, Finnstrom N, et al. (2011) Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 49: 3842-3848.
31. Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, et al. (1999) Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 20: 508-513.
32. Alberti C, Bouakline A, Ribaud P, Lacroix C, Rousselot P, et al. (2001) Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 48: 198-206. (Pubitemid 32677705)
33. Yokoe D, Casper C, Dubberke E, Lee G, Munoz P, et al. (2009) Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. Bone Marrow Transplant 44: 495-507.
34. Meyer BD (1990) Unemployment Insurance and Unemployment Spells. Econometrica 58: 757-782.
35. Heckman JJ, Taber CR (1994) Econometric mixture models and more general models for unobservables in duration analysis. Stat Methods Med Res 3: 279-299.
36. Marino P, Sagaon-Teyssier L, Laetitia M, le Corroller-Soriano AG (2013) Sex Differences in the Return-to-Work Process of Cancer Survivors 2 Years After Diagnosis: Results From a Large French Population-Based Sample. J Clin Oncol 31: 1277-1284.
37. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, et al. (2004) Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 190: 641-649. (Pubitemid 38982107)
38. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56-93.
39. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, et al. (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 46: 709-718.
40. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, et al. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359. (Pubitemid 46148777)